Univariate and multivariate analysis of factors influencing survival
| Variable . | 5-y OS . | 5-y RFS . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis . | Multivariate analysis . | Univariate analysis . | Multivariate analysis . | |||||||||
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Age, y | ||||||||||||
| >60 vs ≤60 | 2.21 | (1.46-3.34) | <.0001 | 1.90 | (1.27-2.83) | .002 | 1.98 | (1.25-3.13) | .001 | 1.57 | (1.01-2.46) | .045 |
| WBC, ×10⁹/L | ||||||||||||
| >50 vs ≤50 | 0.64 | (0.4-1.01) | .093 | NE∗ | 0.99 | (0.6-1.59) | .977 | NE∗ | ||||
| ELN classification | ||||||||||||
| Intermediate vs favorable | 1.80 | (1.22-2.67) | .005 | 1.95 | (1.26-3.00) | .003 | 1.77 | (1.15-2.71) | .012 | 2.04 | (1.28-3.25) | .003 |
| Status | ||||||||||||
| Secondary vs de novo | 1.35 | (0.62-2.92) | .393 | NE∗ | 1.67 | (0.71-3.92) | .142 | 1.21 | (0.59-2.47) | .595 | ||
| Vγ9Vδ2 T cells among LC, % | ||||||||||||
| ≤0.75 vs >0.75 | 1.54 | (1.03-2.31) | .028 | 1.55 | (1.04-2.30) | .030 | 1.69 | (1.09-2.62) | .015 | 1.64 | (1.06-2.53) | .025 |
| HSCT | ||||||||||||
| Yes vs no | 0.46 | (0.28-0.76) | .017 | 0.59 | (0.30-1.16) | .127 | 0.53 | (0.31-0.88) | .045 | 0.38 | (0.17-0.86) | .019 |
| Variable . | 5-y OS . | 5-y RFS . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis . | Multivariate analysis . | Univariate analysis . | Multivariate analysis . | |||||||||
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Age, y | ||||||||||||
| >60 vs ≤60 | 2.21 | (1.46-3.34) | <.0001 | 1.90 | (1.27-2.83) | .002 | 1.98 | (1.25-3.13) | .001 | 1.57 | (1.01-2.46) | .045 |
| WBC, ×10⁹/L | ||||||||||||
| >50 vs ≤50 | 0.64 | (0.4-1.01) | .093 | NE∗ | 0.99 | (0.6-1.59) | .977 | NE∗ | ||||
| ELN classification | ||||||||||||
| Intermediate vs favorable | 1.80 | (1.22-2.67) | .005 | 1.95 | (1.26-3.00) | .003 | 1.77 | (1.15-2.71) | .012 | 2.04 | (1.28-3.25) | .003 |
| Status | ||||||||||||
| Secondary vs de novo | 1.35 | (0.62-2.92) | .393 | NE∗ | 1.67 | (0.71-3.92) | .142 | 1.21 | (0.59-2.47) | .595 | ||
| Vγ9Vδ2 T cells among LC, % | ||||||||||||
| ≤0.75 vs >0.75 | 1.54 | (1.03-2.31) | .028 | 1.55 | (1.04-2.30) | .030 | 1.69 | (1.09-2.62) | .015 | 1.64 | (1.06-2.53) | .025 |
| HSCT | ||||||||||||
| Yes vs no | 0.46 | (0.28-0.76) | .017 | 0.59 | (0.30-1.16) | .127 | 0.53 | (0.31-0.88) | .045 | 0.38 | (0.17-0.86) | .019 |
5-y OS and 5-y RFS were estimated using the Kaplan-Meier method and compared between groups using the log-rank test (n = 198 and 161, respectively). Among the usual AML prognostic factors (age, WBC, ELN 2010 risk category, de novo vs secondary AML, and HSCT), those with a P value <.15 were included in the multivariate logistic regression, with HSCT as a time-dependent covariate (n = 196 and 159 respectively for 5-y OS and 5-y RFS).
LC, lymphocyte; NE, not entered; WBC, white blood cell.
Not entered in the model.